A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01969357

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01969357
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01969357. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
Intervention (Drug)
Placebo
Intervention (Drug)
50 mg SP2086
Intervention (Drug)
100 mg SP2086
Intervention (Drug)
200 mg SP2086
Intervention (Drug)
100 mg Sitagliptin
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01969357
Content hash
231bc5c8cefc1b145cf2c2eeb9d1e15bc785c9077c52ef37b67f30e99887cfe0